Fig. 2

NT-3 maintains the high expression of c-Jun in the denervated distal nerve. a Operational diagram of administration of NT-3 at a total of 2, 4, and 8 µg in 50 µl PBS. b The expression of c-Jun was analyzed using western blotting. c Relative quantitative analysis of the expression of c-Jun. Data normalized to the PBS group. One-way ANOVA with Tukey’s multiple comparison test, *P < 0.05, n = 6. d Immunofluorescence analysis of c-Jun expression in the distal denervated nerve. Scale bar, 50 μm. e The expression of c-Jun analyzed by fluorescence intensity. The expression of c-Jun in the NT-3 (5 W) group is significantly upregulated compared with that in the control (−) group. Unpaired Student’s t-test, ****P < 0.0001, n = 4. f Western blotting used to analyze the expression level of c-Jun in the NT-3 (5 W) and control (−) groups and the distal denervated nerves for 5 weeks. All protein lanes were run on the same gel but were non-contiguous. g Relative quantitative analysis of c-Jun expression shows that NT-3 can maintain a high level of c-Jun. Data were normalized to the control (−) group using one-way ANOVA with Tukey’s multiple comparison test, ***P < 0.001, n = 3. h Schematic showing the location and time of AAV2/9 and NT-3 administration. i Immunofluorescence staining used to analyze the infection efficiency and characteristics of AAV2/9 in the denervated distal stump. Scale bar, 100 μm. j Western blotting used to detect the expression of c-Jun in each group. k Relative quantitative analysis of c-Jun expression shows that sh2 significantly inhibited the expression of c-Jun. Data normalized to WT, one-way ANOVA with Tukey’s multiple comparison test, *P < 0.05, **P < 0.005, n = 3. All numerical data are presented as mean ± SEM